IgE modulation in asthma

Bibliography

• BOULAY ME, BOULET LP: The relationships between atopy, rhinitis and asthma: pathophysiological considerations. Carr: Opin. Allergy Clin. Immune] (2003) 3:51–55.
   PubMed Web of Science ®Google Scholar
• HOWARTH PH, WILSON J, DJUKANOVIC R et al.: Airway inflammation and atopic asthma: a comparative bronchoscopic investigation. kit. Arch. Allergy Appl. Immune]. (1991) 94:266–269.
   PubMed Web of Science ®Google Scholar
• KROEGEL C, JAGER L, WALKER C: Is there a place for intrinsic asthma as a distinct immunopathological entity? Eur: Respir: J. (1997) 10:513–515.
   Google Scholar
• VAN GANSE E, LAFOREST L, PIETRI G et al.: Persistent asthma: disease control, resource utilisation and direct costs. Ear: Respir: (2002) 20:260–267.
   PubMed Web of Science ®Google Scholar
• PLATTS-MILLS TAE: The role of immunoglobulin E in allergy and asthma. Am. J. Respir. Crit. Care Med. (2001) 164:S1–S5.
   Web of Science ®Google Scholar
• SCHULMAN ES: Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am. J. Respir. Crit. Care Med. (2001) 164:S6–S11.
   Web of Science ®Google Scholar
• BONNEFOY J-Y, GAUCHAT J-F, LECOANET-HENCHOZ S, GRABER P, AUBRY J-P: Regulation of human IgE synthesis. Ann. NY Acad. Sci. (1996) 796:59–71.
   PubMed Web of Science ®Google Scholar
• DENT G, HOSKING LA, LORDAN JL et al.: Differential roles of interleukin-16 and CD28/B7 costimulation in the generation of T lymphocyte chemotactic activity in the bronchial mucosa of mild and moderate asthmatic individuals. I Allergy Clin. Immune]. (2002) 110:906–914.
   PubMed Web of Science ®Google Scholar
• KINET J-P: The high-affinity IgE receptor (FcERI): from physiology to pathology. Ann. Rev Immune]. (1999) 17:931–972.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of the high-affinityIgE receptor.
   Google Scholar
• KUBO S, MATSUOKA K, TAYA C et al: Drastic up-regulation of FcERI on mast cells is induced by IgE binding through stabilization and accumulation of FcERI on the cell surface. Immune] (2001) 167:3427–3434.
   PubMed Web of Science ®Google Scholar
• ••Proposed mechanism for the IgE-dependent upregulation of FcERI expression.
   Google Scholar
• YOKOTA A, KIKUTANI H, TANAKA T et al.: Two species of human FcE receptor II (FcERII/CD23): tissue-specific and IL-4-specific regulation of gene expression. Cell (1988) 55:611–618.
   PubMed Web of Science ®Google Scholar
• •Demonstration of heterogeneity of low-affinity IgE receptors.
   Google Scholar
• DELESPESSE G, SUTER U, MOSSALAYI D et al: Expression, structure, and function of the CD23 antigen. Adv. Immune] (1991) 49:149–191.
   PubMed Web of Science ®Google Scholar
• GRANGETTE C, GRUART V, OUAISSI MA et al: IgE receptor on human eosinophils (FcERII): comparison with B cell CD23 and association with an adhesion molecule. Immune] (1989) 143:3580–3588.
   PubMed Web of Science ®Google Scholar
• BOURGET I, DI BERARDINO W, BREITTMAYER JP et al.: CD20 monoclonal antibodies stimulate extracellular cleavage of the low affinity receptor for IgE (FcERII/CD23) in Epstein-Barr-transformed B cells. Biol. Chem. (1994) 269:6927–6930.
   Web of Science ®Google Scholar
• MAYER RJ, FLAMBERG PL, KATCHUR SR et al: CD23 shedding: requirements for substrate recognition and inhibition by dipeptide hydroxamic acids. Inflamm. Res. (2002) 51:85–90.
   PubMed Web of Science ®Google Scholar
• •Structure-activity study of inhibition of CD23 cleavage by hydroxarnic acid derivative protease inhibitors.
   Google Scholar
• SUTTON BJ, GOULD HJ: The human IgE network. Nature (1993) 366:421–428.
   PubMed Web of Science ®Google Scholar
• •Review of IgE function.
   Google Scholar
• MITCHELL EB, CROW J, ROWNTREE S, WEBSTER ADB, PLATTS-MILLS TA: Cutaneous basophil hypersensitivity to inhalant allergens in atopic dermatitis patients: elicitation of delayed responses containing basophils following local transfer of immune serum but not IgE antibody. Invest. Dermatol (1984) 83:290–295.
   PubMed Web of Science ®Google Scholar
• WATSON N, BODTKE K, COLEMAN RA et al.: Role of IgE in hyperresponsiveness induced by passive sensitization of human airways. Am. J. Respir. Grit. Care Med. (1997) 155:839–844.
   PubMed Web of Science ®Google Scholar
• SCHMIDT D, RUEHLMANN E, BRANSCHEID D, MAGNUSSEN H, RABE KF: Passive sensitization of human airways increases responsiveness to leukotriene C4. Eur: Respir. J. (1999) 14:315–319.
   Google Scholar
• •Demonstration of LTC4 hyper-responsiveness induced by passive sensitisation.
   Google Scholar
• HAKONARSON H, HERRICK DJ, GRUNSTEIN MM: Mechanism of impaired P-adrenoceptor responsiveness in atopic sensitized airway smooth muscle. Am. J. Physic] (1995) 269:L645–L652.
   Google Scholar
• •Demonstration of I3-agonist hyporesponsiveness induced by passive sensitisation.
   Google Scholar
• RABE KF, WATSON N, DENT G et al: Inhibition of human airway sensitization by a novel monoclonal anti-IgE antibody, 17-9. Am. J. Respir. Grit. Care Med. (1998) 157:1429–1435.
   PubMed Web of Science ®Google Scholar
• ••Characterisation of the involvement of IgEin passive sensitisation and induction of nonspecific hyper-responsiveness.
   Google Scholar
• CORNE J, DJUKANOVIC R, THOMAS L et al: The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. Clin. Invest. (1997) 99:879–887.
   Google Scholar
• ••Phase I study of an anti-IgE antibody.
   Google Scholar
• COYLE AJ, WAGNER K, BERTRAND C,TSUYUKI S, BEWS J, HEUSSER C: Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. I Exp. Med. (1996) 183:1303–1310.
   PubMed Web of Science ®Google Scholar
• ISHIZAKA K, ISHIZAKA T: Biological function of yE antibodies and mechanisms of reaginic hypersensitivity. Gin. Exp. Immune] (1970) 6:25–42.
   PubMed Web of Science ®Google Scholar
• ••Description of IgE actions through specificreceptors.
   Google Scholar
• PRESTA LG, LAHR SJ, SHIELDS RL et al.: Humanization of an antibody directed against IgE. Immune] (1993) 151:2623–2632.
   PubMed Web of Science ®Google Scholar
• •Description of process for producing humanised anti-IgE antibodies.
   Google Scholar
• SABAN R, HAAK-FRENDSCHO M, ZINE M et al: Human FcERII-IgG and humanized anti-IgE monoclonal antibody MaEll block passive sensitization of human and rhesus monkey lung. J. Allergy Gin. Immune]. (1994) 94:836–843.
   PubMed Web of Science ®Google Scholar
• •Demonstration of in vivo inhibition of passive sensitisation by anti-IgE.
   Google Scholar
• MILGROM H, FICK RB Jr, SU JQ et al.: Treatment of allergic asthma with monoclonal anti-IgE antibody: rhuMAb-E25 Study Group. N Engl. Med. (1999) 341:1966–1973.
   PubMed Web of Science ®Google Scholar
• D'AMATO G: Therapy of allergic bronchial asthma with omalizumab - an anti-IgE monoclonal antibody. Expert Opin. Biol. Ther. (2003) 3:371–376.
   Google Scholar
• MACGLASHAN DW Jr, BOCHNER BS, ADELMAN DC et al: Down-regulation of FcERI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol (1997) 158:1438–1445.
   PubMed Web of Science ®Google Scholar
• •Demonstration of in vivo blockade of IgE-dependent FcERI expression by anti-IgE.
   Google Scholar
• BOULET L-P, CHAPMAN KR, COTE. J et al.: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic responses. Am..]: Respir. Grit. Care Med. (1997) 155:1835–1840.
   Google Scholar
• ••Earliest Phase II study of clinical actionsof anti-IgE.
   Google Scholar
• FAHY JV, FLEMING HE, WONG HH et al.: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. I Respir. Grit. Care Med. (1997) 155:1828–1834.
   PubMed Web of Science ®Google Scholar
• ••Earliest Phase II study of clinical actionsof anti-IgE.
   Google Scholar
• SOLER M, MATZ J, TOWNLEY R et al.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Ear: Respir. J. (2001) 18:254–261.
   PubMed Web of Science ®Google Scholar
• BUHL R, HANF G, SOLER M et al: The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Ear: Respir. (2002) 20:1088–1094.
   PubMed Web of Science ®Google Scholar
• NOGA O, HANF G, KUNKEL G: Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int. Arch. Allergy kimono]. (2003) 131:46–52.
   PubMed Web of Science ®Google Scholar
• BUSSE WW, CORREN J, LANIER BQ et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. Allergy Clin. Immunol (2001) 108:184–190.
   Google Scholar
• •Phase III study of anti-IgE in severe asthma.
   Google Scholar
• BUSSE WW: Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am. J. Respir. Grit. Care Med. (2001) 164:S12–S17.
   Web of Science ®Google Scholar
• BUHL R, SOLER M, MATZ J et al: Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Ear: Respir. J. (2002) 20:73–78.
   PubMed Web of Science ®Google Scholar
• BUHL R: Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review. Respir. Med. (2003) 97:123–129.
   PubMed Web of Science ®Google Scholar
• CORREN J, CASALE T, DENIZ Y, ASHBY M: Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. I Allergy Clin. Immunol (2003) 111:87–90.
   PubMed Web of Science ®Google Scholar
• FINN A, GROSS G, VAN BAVEL J et al:Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. I Allergy Clin. Immunol (2003) 111:278–284.
   PubMed Web of Science ®Google Scholar
• DJUKANOVIC R, WILSON SJ, KRAFT M et al.: Effect of treatment with anti-IgE antibody (omalizumab) on airway inflammation in mild atopic asthma. Am. I Respir. Crit. Care Med. (2003) 167:A703.
   Google Scholar
• NO AUTHORS LISTED: Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25. BioDrugs (2002) 16:380–386.
   PubMed Web of Science ®Google Scholar
• •Review of clinical data from anti-IgE studies.
   Google Scholar
• GREMBIALE RD, CAMPOROTA L, NATY S, TRANFA CM, DJUKANOVIC R, MARSICO SA: Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am. J. Respir. Grit. Care Med. (2000) 162:2048–2052.
   PubMed Web of Science ®Google Scholar
• BACHMANN MF, ZINKERNAGEL RM: Neutralizing antiviral B cell responses.Ann. Rev. Immunol (1997) 15:235–270.
   PubMed Web of Science ®Google Scholar
• HAKONARSON H, MASKERI N, CARTER C, CHUANG S, GRUNSTEIN MM: Autocrine interaction between IL-5 and IL-1-13 mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle. I. Clin. Invest. (1999) 104:657–667.
   PubMed Web of Science ®Google Scholar
• GRUNSTEIN MM, HAKONARSON H, LEITER J et al.: IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle. Am..! Physiol (2002) 282:L520–L528.
   Web of Science ®Google Scholar
• •Demonstration of a role for IL-13 in the induction of nonspecific hyper-responsiveness by passive sensitisation.
   Google Scholar
• GRUNER S, LIEBENTHAL C, HEUSSER C et al.: The influence of interferon-y and interleulkin-4 on IgE production in B lymphocytes of patients with atopic dermatitis: a possible criterion for selection of patients for interferon therapy. Acta Berm. Venereol (1991) 71:484–487.
   PubMed Web of Science ®Google Scholar
• WU CY, BRINKMANN V, COX D, HEUSSER C, DELESPESSE G: Modulation of human IgE synthesis by transforming growth factor-P. Clin. Immunol Immunopathol (1992) 62:277–284.
   PubMedGoogle Scholar
• ARMANT M, ISHIHARA H, RUBIO M, DELESPESSE G, SARFATI M: Regulation of cytokine production by soluble CD23: costimulation of interferon-y secretion and triggering of tumor necrosis factor a release. J. Exp. Med. (1994) 180:1005–1011.
   PubMed Web of Science ®Google Scholar
• LECOANET-HENCHOZ S, GAUCHAT JF, AUBRY JP et al.: CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18. Immunity(1995) 3:119–125.
   PubMed Web of Science ®Google Scholar
• •Demonstration of cytokine-like actions of sCD23.
   Google Scholar
• MAYER RJ, BOLOGNESE BJ, AL MAHDI N et al: Inhibition of CD23 processing correlates with inhibition of IL-4-stimulated IgE production in human PBL and hu-PBL-reconstituted SCID mice. Clin. Exp. Allergy (2000) 30:719–727.
   PubMed Web of Science ®Google Scholar
• ••Description of the role of sCD23 inpromoting IgE secretion in vivo.
   Google Scholar